Jump to content


New Criterion for Restarting Therapy in CML

  • Please log in to reply
No replies to this topic

#1 GerryL


    New Member

  • Members
  • Pip
  • 0 posts

Posted 10 March 2014 - 01:54 AM

Life-long therapy with tyrosine kinase inhibitors (TKIs) is still the consensus treatment for patients with chronic myeloid leukemia (CML), but researchers are examining the feasibility of discontinuing therapy in select individuals. The latest study on this approach, known as the A-STIM (According to Stop Imatinib) trial, suggests that patients should be evaluated for loss of major molecular response (MMR). This could be used as a criterion for resuming therapy.


1 user(s) are reading this topic

0 members, 1 guests, 0 anonymous users